'Exciting Time for NASH' With Resmetirom Phase 3 Results at HealthBulance.

Health care is our expertise. VIENNA — Resolution of non-alcoholic steatohepatitis (NASH), and reduction of fibrosis on liver biopsy were achieved with the oral, thyroid hormone receptor beta-selective agonist resmetirom (Madrigal Pharmaceuticals) in patients with NASH and associated cirrhosis in a

Medscape

'Exciting Time for NASH' With Resmetirom Phase 3 Results

'Exciting Time for NASH' With Resmetirom Phase 3 Results

VIENNA — Resolution of non-alcoholic steatohepatitis (NASH), and reduction of fibrosis on liver biopsy were achieved with the oral, thyroid hormone receptor beta-selective agonist resmetirom (Madrigal Pharmaceuticals) in patients with NASH and associated cirrhosis in a pivotal phase 3 clinical trial. The primary results of the MAESTRO-NASH (NCT03900429) trial were reported here at the European Association for the Study of the Liver (EASL) Congress 2023.